Continuation Study of Long-term Safety, Tolerability, Pharmacokinetics and Efficacy of Recifercept in Achondroplasia

NCT05116046 · clinicaltrials.gov ↗
PHASE2
Phase
TERMINATED
Status
35
Enrollment
INDUSTRY
Sponsor class

Stopped The study was terminated due to lack of efficacy at any of the tested doses on 18th November 2022. The decision to terminate the study is not related to a safety concern.

Conditions

Interventions

Sponsor

Pfizer